Latest Healthcare Technology News

IMEXHS Limited reported modest revenue growth and a 16% increase in ARR in Q1 FY25, alongside the commercial rollout of its Aquila+ radiology platform and a $2.5 million capital raising to fuel expansion.

dorsaVi’s Q3 FY25 report reveals growing adoption of its AI-powered video movement analysis in the US, a new elite athlete research partnership, and the launch of a pioneering 3D ACL injury prevention test.

PainChek Limited reports strong progress toward FDA De Novo clearance for US market entry, launches its Infant App in Australia, and achieves robust global licence growth with a 30% year-on-year revenue increase.

Visionflex Group reported a 46% year-on-year rise in annual recurring revenue to $1.7 million, secured key contracts including a $1 million virtual nursing pilot, and targets operating cash flow positivity in Q4 FY25.

Mach7 Technologies reported a robust Q3 FY25 with a CARR of A$30.8 million and positive operating cash flow, while announcing a leadership change and reaffirming growth guidance.

Micro-X Ltd has secured a $5.6 million strategic partnership with Malaysian firm Billion Prima and raised $4 million in capital, marking a pivotal shift towards medical imaging while progressing key security and health technology projects.

Santos Limited’s 2024 Annual Report reveals a 5% decline in production and a 9% drop in sales revenue, yet highlights significant progress in carbon capture and storage and emissions reduction targets.

Alcidion Group Limited reported a robust Q3 FY25 with $13.1 million in cash receipts and a landmark 10-year $37.5 million contract with North Cumbria NHS Trust, prompting an upgrade to its full-year EBITDA guidance.

Enlitic has announced a strategic collaboration with GE HealthCare to deploy AI-driven technology that will transform the migration of medical imaging data, promising faster, more secure transitions and enhanced data quality for healthcare providers worldwide.

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.25 per share for the six months ending December 2024, signaling continued shareholder returns without the need for external approvals.

Pro Medicus Limited delivered a robust half-year performance ending December 2024, with after-tax profits soaring 42.7% to $51.74 million and revenues climbing 31.1% to $97.2 million, driven by significant contract wins in North America and sustained growth in Australia.